Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 6:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1777–1800 of 3,528 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: biospecimen Collection Clear all

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions: Biospecimen Collection, Chest Computed Tomography, Echocardiography, Hematopoietic Cell Transplantation, Methotrexate, Multigated Acquisition Scan, Ruxolitinib Phosphate, Tacrolimus; Procedure · Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 2 Years to 22 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Duarte, California

Conditions: Head and Neck Squamous Cell Carcinoma, Stage I Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage II Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
Interventions: Gabapentin, Placebo, Chemotheraphy, Radiation Therapy, Analgesic Agent, Biospecimen Collection, Survey Administration; Drug · Radiation · Procedure + 1 more
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 216
States / cities: Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 175 more

Conditions: Urolithiasis, Stones, Kidney, Renal Stones, Kidney Stones
Interventions: CVAC® SYSTEM, FLEXIBLE AND NAVIGATIONAL URETERAL ACCESS SHEATH (FANS) IN FLEXIBLE URETEROSCOPY (FURS), DIRECT IN-SCOPE SUCTION (DISS) IN FLEXIBLE URETEROSCOPY (FURS), URETEROSCOPY (URS) WITHOUT SUCTION, PERCUTANEOUS NEPHROLITHOTOMY (PCNL); Device · Procedure
Lead sponsor: Calyxo, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 10
States / cities: Miami, Florida • Wichita, Kansas • Cheektowaga, New York + 6 more

Conditions: Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Hereditary Breast/Ovarian Cancer (brca1, brca2), Ovarian Cancer, Sarcoma, Uterine Leiomyomata, Vaginal Cancer, Vulvar Cancer
Interventions: Ca-125, screening questionnaire administration, Surgery; Other · Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 6,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2040
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Colorectal Carcinoma
Interventions: Biospecimen Collection, Survey Administration; Procedure · Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 45 Years and older · Female only
Enrollment: 146 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: CMV, CMV Infection, Hematopoietic Cell Transplant
Interventions: Letermovir Pill, blood draw; Drug · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 12 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 2
States / cities: Minneapolis, Minnesota • New York, New York

Conditions: Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma, Recurrent Platinum-Sensitive Ovarian High Grade Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Ovarian High Grade Serous Adenocarcinoma, Recurrent Platinum-Sensitive Primary Peritoneal Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Primary Peritoneal High Grade Serous Adenocarcinoma
Interventions: Anti-VEGF Monoclonal Antibody, Bevacizumab, Biospecimen Collection, Carboplatin, Computed Tomography, Echocardiography Test, Gemcitabine, Magnetic Resonance Imaging, Multigated Acquisition Scan, Pegylated Liposomal Doxorubicin Hydrochloride, Sacituzumab Govitecan; Biological · Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 23
States / cities: Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 18 more

Conditions: Myotonic Dystrophy
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 5 Years and older
Enrollment: 215 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 3
States / cities: Boston, Massachusetts • Dallas, Texas

Conditions: Cervical Cancer
Interventions: CHW and Self-sampling for Cervical Cancer, Mailed Self Sampler; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 30 Years to 65 Years · Female only
Enrollment: 602 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Tobacco-Related Carcinoma
Interventions: Biospecimen Collection, Cigarette, Nicotine Oral Pouch, Smokeless Tobacco, Survey Administration, Text Message-Based Navigation Intervention; Procedure · Drug · Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Diabetes Mellitus
Interventions: SmartAlbu; Device
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions: Non-Interventional Study; Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 7 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Duarte, California

Conditions: COVID-19
Interventions: RT-PCR Test, Real-time PCR Test; Diagnostic Test
Lead sponsor: QuantuMDx Group Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 877 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: Miami, Florida • Knoxville, Tennessee • Memphis, Tennessee

Conditions: SARS-CoV-2, Influenza A, Influenza B, Asymptomatic COVID-19
Interventions: LumiraDx SARS-CoV-2 & Flu A/B; Diagnostic Test
Lead sponsor: LumiraDx UK Limited; Industry
Eligibility: 2 Years and older
Enrollment: 1,081 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Cullman, Alabama

Conditions: Delirium, Hip Arthroplasty, Elderly
Interventions: Blood Draw, Cerebral Spinal Fluid collection, Electroencephalogram, Cerebral blood flow and oxygen extraction fraction; Procedure · Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: 65 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Gastrointestinal Diseases
Interventions: Biopsy and fluid samples; Other
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Total Joint Arthroplasty, Periprosthetic Joint Infections
Interventions: Blood Draw or Saliva/Cheek Cell Sample:; Genetic
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 100 Years
Enrollment: 150 participants
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Tobacco-Related Carcinoma, Smoking Cessation
Interventions: Smoking cessation education, Survey Administration, Telephone-Based Intervention, Urine Specimen Collection, Silicone Wrist Band, Interview, Focus Group; Other · Behavioral · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 760 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Core Binding Factor Acute Myeloid Leukemia
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Cytarabine, Daunorubicin Hydrochloride, Echocardiography Test, Gemtuzumab Ozogamicin, Multigated Acquisition Scan, Venetoclax; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 59 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 79
States / cities: Birmingham, Alabama • La Jolla, California • Pembroke Pines, Florida + 66 more

Conditions: Niemann-Pick Disease, Type C
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 1 Day to 120 Years
Enrollment: 900 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Autoimmune Disease, Crohn Disease, Dermatomyositis, Hematopoietic and Lymphoid Cell Neoplasm, Inflammatory Bowel Disease, Malignant Solid Neoplasm, Multiple Sclerosis, Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Sjogren Syndrome, Systemic Lupus Erythematosus, Systemic Scleroderma, Ulcerative Colitis
Interventions: Biospecimen Collection, Cabozantinib, Fluoropyrimidine, Ipilimumab, Nivolumab, Platinum Compound, Platinum Doublet; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 51
States / cities: Birmingham, Alabama • Palo Alto, California • Sacramento, California + 37 more

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Magnetic Resonance Imaging, Pirtobrutinib, Positron Emission Tomography, Venetoclax, Echocardiography, Multigated Acquisition Scan, Biopsy; Procedure · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Smoking Cessation, Smoking Cessation Counseling Ability and Practice, Smoking Cessation Counselling, Lung Cancer Screening
Interventions: CONNECT Intervention for multilingual populations, Saliva Sample, Interview; Behavioral · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 50 Years to 80 Years
Enrollment: 439 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Systemic Mastocytosis
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Search by objective public record fields.

Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer

Stone Clearance With Aspiration vs Other Technologies: a Real-world Evidence Study

Specimen and Data Study for Ovarian Cancer Early Detection and Prevention

Blood Test (Guardant Shield™) for Screening of Colorectal Cancer in Underserved Patients

A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection

Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy

Extracellular RNA Biomarkers of Myotonic Dystrophy

Using CHWs or Mailing Self Sampling Home Tests to Increase Cervical Cancer Screening in South Florida

Informing Oral Nicotine Pouch Regulations to Promote Public Health

Salivary Glycated Albumin

Kinetic Analysis of Immune Cells in Blood and Chronic Graft-Versus-Host Disease-Affected Tissues After Allogeneic Hematopoietic Cell Transplantation

Q-POC SARS-CoV-2 Assay COVID-19 Clinical Evaluation

Clinical Validation of the LumiraDx SARS-CoV-2 & Flu A/B Combo Test

Delirium, Intraoperative Cerebral Perfusion and EEG Abnormalities After Total Hip Arthroplasty

Foregut Leaks-Role of Microbiome

Genetic Susceptibility to Periprosthetic Joint Infections

Healthy Family Project: Tobacco Use and Smoke Exposure in Asian American Communities

Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)

Evaluation of Biochemical Markers and Clinical Investigation of Niemann-Pick Disease, Type C

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia

Evaluating the Impact of CONNECT in a Multilingual Population

Precision Medicine for Indolent Systemic Mastocytosis (PRISM)